Abstract
Purpose
To describe the experience of our Division of Endocrinology with multikinase inhibitor (MKI) treatment in radioiodine-resistant differentiated thyroid cancer (DTC) patients.
Methods
Adults patients with a diagnosis of DTC treated with an MKI drug from March 2011 to October 2018 were registered into a retrospective database. Primary objectives were: the assessment of progression-free survival (PFS) and radiographic response evaluated according to RECIST v. 1.1. Adverse events (AEs) were evaluated by using Common Terminology Criteria for Adverse Events v. 5.0.
Results
Twenty-two patients were treated with MKIs (21 with sorafenib, one with lenvatinib as first-line treatment). Seven patients required a second-line therapy with lenvatinib and one patient required a third-line treatment with pazopanib. Median duration of treatment was 11.2 (4.8–79.6) months. Best responses with sorafenib were partial response (PR) in two patients (11%), stable disease (SD) >6 months in 13 patients (72%), and progressive disease (PD) in three patients (17%). Best responses with second-line lenvatinib were PR in one patient (33%) and SD in two patients (66%). Median PFS was 31.5 months. AEs were present in 19 (90%) patients under sorafenib. The most common AEs were hand–foot syndrome (HFS) (67%), diarrhea (52%), and hypertension (52%). Definitive withdrawal was necessary in only one patient (4.7%).
Conclusions
Our study reflects the real-world clinical experience of an Endocrinology Division on the management of radioiodine-resistant DTC patients with sorafenib and lenvatinib, showing a beneficial therapeutic effect with acceptable tolerability.
Similar content being viewed by others
References
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006)
A. Albero, J.E. Lopez, A. Torres, L. de la Cruz, T. Martin, Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr. Relat. Cancer 23, R71–R84 (2016)
M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger, Sorafenib in locally advanced or metastatic, radioactive iodine- refractory, differentiated thyroid cancer: a randomized, double- blind, phase 3. DECISION trial. Lancet 384, 319–328 (2014)
M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015)
E.E. Cohen, L.S. Rosen, E.E. Vokes, M.S. Kies, A.A. Forastiere, F.P. Worden, M.A. Kane, E. Sherman, S. Kim, P. Bycott, M. Tortorici, D.R. Shalinsky, K.F. Liau, R.B. Cohen, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 26, 4708–4713 (2008)
K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, M.E. Menefee, J. Rubin, K. Sideras, J.C. Morris III., B. McIver, J.K. Burton, K.P. Webster, C. Bieber, A.M. Traynor, P.J. Flynn, B.C. Goh, H. Tang, S.P. Ivy, C. Erlichman, Efficacy of pazopanib in progressive, radioiodine refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962–972 (2010)
L.L. Carr, D.A. Mankoff, B.H. Goulart, K.D. Eaton, P.T. Capell, E.M. Kell, J.E. Bauman, R.G. Martins, Phase II study of daily sunitinib in FDG-PET-positive, iodine refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16, 5260–5268 (2010)
M.E. Cabanillas, J.A. de Souza, S. Geyer, L.J. Wirth, M.E. Menefee, S.V. Liu, K. Shah, J. Wright, M.H. Shah, Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a Multicenter Phase II International Thyroid Oncology Group Trial. J. Clin. Oncol. 35, 3315–3321 (2017)
B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)
M.S. Brose, J. Smit, C.C. Lin, F. Pitoia, M. Fellous, Y. DeSanctis, M. Schlumberger, M. Tori, I. Sugitani, Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr. Relat. Cancer 24, 237–242 (2017)
M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2, 356–358 (2014)
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)
National Cancer Institute. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 09 Oct 2018
M.E. Cabanillas, S.G. Waguespack, Y. Bronstein, M.D. Williams, L. Feng, M. Hernandez, A. Lopez, S.I. Sherman, N.L. Busaidy, Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J. Clin. Endocrinol. Metab. 95, 2588–2595 (2010)
M. Molina-Vega, J. García-Alemán, A. Sebastián-Ochoa, I. Mancha-Doblas, J.M. Trigo-Pérez, F. Tinahones-Madueño, Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine 59, 395–401 (2018)
M.H. Massicotte, M. Brassard, M. Claude-Desroches, I. Borget, F. Bonichon, A.L. Giraudet, C. Do Cao, C.N. Chougnet, S. Leboulleux, E. Baudin, M. Schlumberger, C. de la Fouchardière, Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur. J. Endocrinol. 170, 575–582 (2014)
R. Dadu, C. Devine, M. Hernandez, S.G. Waguespack, N.L. Busaidy, M.I. Hu, C. Jimenez, M.A. Habra, R.V. Sellin, A.K. Ying, G.J. Cote, S.I. Sherman, M.E. Cabanillas, Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J. Clin. Endocrinol. Metab. 99, 2086–2094 (2014)
R. Copher, O. Adejoro, S.D. Byfield, M. DuCharme, D. Chatterjee, P.R. Joshi, A. Desai, M.A. Baig, Second or none: many patients treated for refractory differentiated thyroid cancer with small molecular kinase inhibitors do not receive a second line of therapy. J. Clin. Oncol. 35(15_suppl), e17589 (2017)
R.P. Dang, D. McFarland, V.H. Le, N. Camille, B.A. Miles, M.S. Teng, E.M. Genden, K.J. Misiukiewicz, Neoadjuvant therapy in differentiated thyroid cancer. Int. J. Surg. Oncol. 2016, 3743420 (2016)
D.L.S. Danilovic, G. Castro Jr., F.S.R. Roitberg, F.A.B. Vanderlei, F.A. Bonani, R.M.C. Freitas, G.B. Coura-Filho, R.Y. Camargo, M.A. Kulcsar, S. Marui, A.O. Hoff, Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch. Endocrinol. Metab. 62, 370–375 (2018)
M.S. Brose, C.T. Frenette, S.M. Keefe, S.M. Stein, Management of sorafenib-related adverse events: a clinician’s perspective. Semin. Oncol. 41, S1–S16 (2014)
T.E. Hutson, J. Bellmunt, C. Porta, C. Szczylik, M. Staehler, A. Nadel, S. Anderson, R. Bukowski, T. Eisen, B. Escudier; Sorafenib TARGET Clinical Trial Group, Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur. J. Cancer 46, 2432–2440 (2010)
W.X. Qi, Z. Shen, L.N. Tang, Y. Yao, Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br. J. Clin. Pharmacol. 78, 748–762 (2014)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Fabián Pitoia is medical advisor, speaker and Steering Committee Bayer. Consultancy for Sanofi and Raffo Laboratories. The remaining authors declare that they have no conflict of interest.
Ethical approval
The study was approved by the Institutional Review Board.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jerkovich, F., García Falcone, M.G. & Pitoia, F. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64, 632–638 (2019). https://doi.org/10.1007/s12020-019-01883-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01883-3